{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:01:49Z","timestamp":1788454909794,"version":"build-2803163510"},"reference-count":38,"publisher":"Informa UK Limited","issue":"5","license":[{"start":{"date-parts":[[2021,4,4]],"date-time":"2021-04-04T00:00:00Z","timestamp":1617494400000},"content-version":"unspecified","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Human Vaccines & Immunotherapeutics"],"published-print":{"date-parts":[[2021,5,4]]},"DOI":"10.1080\/21645515.2020.1812315","type":"journal-article","created":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T15:11:17Z","timestamp":1605107477000},"page":"1366-1373","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":8,"title":["Safety and immunogenicity of a new Sabin inactivated poliovirus vaccine candidate produced on the PER.C6\u00ae cell-line: a phase 1 randomized controlled trial in adults"],"prefix":"10.1080","volume":"17","author":[{"given":"Isabel","family":"Leroux-Roels","sequence":"first","affiliation":[{"name":"Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5968-2542","authenticated-orcid":false,"given":"Geert","family":"Leroux-Roels","sequence":"additional","affiliation":[{"name":"Ghent University and Ghent University Hospital","place":["Ghent, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgi","family":"Shukarev","sequence":"additional","affiliation":[{"name":"Janssen Vaccines AG","place":["Bern, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8563-2266","authenticated-orcid":false,"given":"Hanneke","family":"Schuitemaker","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7108-1168","authenticated-orcid":false,"given":"Conor","family":"Cahill","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2255-2810","authenticated-orcid":false,"given":"Richard","family":"de Rooij","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals","place":["Zurich, Switzerland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Struijs","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hester","family":"van Zeeburg","sequence":"additional","affiliation":[{"name":"DCPrime BV","place":["Leiden the Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-7022","authenticated-orcid":false,"given":"Jeanne-Marie","family":"Jacquet","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V","place":["Leiden, The Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,11]]},"reference":[{"key":"e_1_3_3_2_1","doi-asserted-by":"publisher","DOI":"10.1177\/004947558301300108"},{"key":"e_1_3_3_3_1","unstructured":"WHA 41st World Health Assembly. Global eradication of poliomyelitis by 2000. Geneva World Health Organization [resolution WHA41.28]. 1988 [accessed 2020 Mar 16]. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/19880513_resolution-2.pdf."},{"key":"e_1_3_3_4_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6718a4"},{"key":"e_1_3_3_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)32442-X"},{"key":"e_1_3_3_6_1","unstructured":"World Health organization. Global polio eradication initiative. Polio this week. 2020 [accessed 2020 Mar 16]. http:\/\/polioeradication.org\/polio-today\/polio-now\/this-week\/."},{"key":"e_1_3_3_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu128"},{"key":"e_1_3_3_8_1","unstructured":"World Health Assembly. Poliomyelitis: mechanism for management of potential risks to eradication. Geneva: World Health Organization [resolution WHA61.1]. 2008 [accessed 2020 Mar 16]. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/WHA61_Resolution_English.pdf."},{"key":"e_1_3_3_9_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6535a3"},{"key":"e_1_3_3_10_1","unstructured":"Global Polio Eradication Initiative. Polio eradication and endgame strategic plan 2013\u20132018. 2013 [accessed 2020 Mar 16]. http:\/\/polioeradication.org\/wp-content\/uploads\/2016\/07\/PEESP_EN_A4.pdf."},{"key":"e_1_3_3_11_1","first-page":"5","article-title":"Meeting of the strategic advisory group of experts on immunization, November 2012 \u2013 conclusions and recommendations. Polio eradication","volume":"88","author":"World Health Organization","year":"2013","unstructured":"World Health Organization. Meeting of the strategic advisory group of experts on immunization, November 2012 \u2013 conclusions and recommendations. Polio eradication. Weekly Epidemiological Rec 2013;88:5\u20137.","journal-title":"Weekly Epidemiological Rec"},{"key":"e_1_3_3_12_1","first-page":"145","article-title":"Polio vaccines: WHO position paper - March 2016","volume":"12","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Polio vaccines: WHO position paper - March 2016. Weekly Epidemiological Rec 2016;12:145\u201368.","journal-title":"Weekly Epidemiological Rec"},{"key":"e_1_3_3_13_1","unstructured":"Global Polio Eradication Initiative. Polio post-certification strategy: a risk mitigation strategy for a polio-free world. Geneva: World Health Organization. License: CC BY-NC-SA 3.0 IGO. 2018 [accessed 2020 Mar 16]. http:\/\/polioeradication.org\/wp-content\/uploads\/2018\/04\/polio-post-certification-strategy-20180424-2.pdf."},{"key":"e_1_3_3_14_1","first-page":"308","article-title":"Meeting of the strategic advisory group of experts on immunization, April 2017 \u2013 conclusions and recommendations. Polio Eradication","volume":"92","author":"World Health Organization","year":"2017","unstructured":"World Health Organization. Meeting of the strategic advisory group of experts on immunization, April 2017 \u2013 conclusions and recommendations. Polio Eradication. Weekly Epidemiological Rec 2017;92:308\u201310.","journal-title":"Weekly Epidemiological Rec"},{"key":"e_1_3_3_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biologicals.2016.08.005"},{"key":"e_1_3_3_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005316"},{"key":"e_1_3_3_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix038"},{"key":"e_1_3_3_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30177-9"},{"key":"e_1_3_3_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.021"},{"key":"e_1_3_3_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.109"},{"key":"e_1_3_3_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir723"},{"key":"e_1_3_3_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit155"},{"key":"e_1_3_3_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.07.029"},{"key":"e_1_3_3_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw433"},{"key":"e_1_3_3_25_1","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2018.1504538"},{"key":"e_1_3_3_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.023"},{"key":"e_1_3_3_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.11.015"},{"key":"e_1_3_3_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.10.070"},{"key":"e_1_3_3_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.10.091"},{"key":"e_1_3_3_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.09.068"},{"key":"e_1_3_3_31_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_3_32_1","unstructured":"EMA. ICH good clinical practice guidelines. 2016 [accessed 2020 Jul 16]. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-6-r2-guideline-good-clinical-practice-step-5_en.pdf."},{"key":"e_1_3_3_33_1","unstructured":"Food and Drug Administration. Center for biologics evaluation and research. guidance for industry. Toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007 Sept."},{"key":"e_1_3_3_34_1","unstructured":"World Health Organization. Expert committee on biological standardization (ECBS) sixty-fifth report. Recommendations to assure the quality safety and efficacy of poliomyelitis vaccines (inactivated). WHO Technical Report Series No. 993 Annex 3 2015."},{"key":"e_1_3_3_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-3292-4_8"},{"key":"e_1_3_3_36_1","unstructured":"KCE Report 313. Performance of the Belgian health system \u2013 report 2019. [accessed 2020 Jul 16] https:\/\/www.healthybelgium.be\/metadata\/hspa\/p1_p2_p3.pdf."},{"key":"e_1_3_3_37_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-198811000-00003"},{"key":"e_1_3_3_38_1","unstructured":"World Health Organization. Expert committee on biological standardization Geneva 29 October to 2 November 2018. Report on the WHO collaborative study to establish the 1st International Standard for Sabin inactivated polio vaccine (sIPV). 2018 [accessed 2020 Mar 16]. http:\/\/www.who.int\/biologicals\/BS.2018.2338_sIPV_IS_Collaborative_Study_Report_version.pdf."},{"key":"e_1_3_3_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix110"}],"container-title":["Human Vaccines & Immunotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/21645515.2020.1812315","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T18:43:00Z","timestamp":1768329780000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/21645515.2020.1812315"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,11]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,5,4]]}},"alternative-id":["10.1080\/21645515.2020.1812315"],"URL":"https:\/\/doi.org\/10.1080\/21645515.2020.1812315","relation":{},"ISSN":["2164-5515","2164-554X"],"issn-type":[{"value":"2164-5515","type":"print"},{"value":"2164-554X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,11]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=khvi20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}